Company: PTPI
Filing Date: 2025-02-13
Form Type: S-1/A
Source: 0001410578-25-000122
Chunk: 206

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-13
Form: S-1/A
Chunk 206
---
 — | ​ | ​    |            — |
| ​                                            | ​ | ​                   |            ​ | ​ | ​    |            ​ |
| Net loss                                     | ​ | $                   |   -8,163,188 | ​ | $    |  -20,037,573 |
| ​                                            | ​ | ​                   |            ​ | ​ | ​    |            ​ |
| Preferred Stock dividend and cash premiums   | ​ | ​                   |     -821,456 | ​ | ​    |            — |
| Preferred Stock accretion                    | ​ | ​                   |   -4,829,755 | ​ | ​    |            — |
| ​                                            | ​ | ​                   |            ​ | ​ | ​    |            ​ |
| Net loss attributable to common stockholders | ​ |                     |  -13,814,399 | ​ |      |  -20,037,573 |
| Basic and Diluted                            | ​ | $                   |        -6.35 | ​ | $    |        -9.68 |
| Weighted average common shares outstanding   | ​ |                     |            ​ | ​ |      |            ​ |
| Basic and Diluted                            | ​ |                     |    2,176,017 | ​ |      |    2,070,210 |

The accompanying Notes are an integral part of the Consolidated Financial Statements.

F-5

PETROS PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY

| ​                                                                                                            
 ​                                                                                                            
 ​                                                                                                            
 ​                                                                                                            
 ​                                                                                                            
 ​                                                                                                            
 Year Ended December 31, 2023                                                                                 | ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ |           ​ 
           ​ 
 Convertible 
  Redeemable 
   Preferred 
       Stock 
           ​ | ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ | ​           
 Convertible 
 Redeemable  
 Preferred   
 Stock       
 Amount      
 ​           |          ​ 
          ​ | ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ |         ​ 
         ​ 
         ​ 
         ​ 
    Common 
     Stock 
         ​ | ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ | ​      
 ​      
 ​      
 Common 
 Stock  
 Amount 
 ​      |   ​ 
   ​ 
   ​